Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - HC Wainwright increased their FY2024 earnings per share (EPS) estimates for Astria Therapeutics in a research report issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings of ($1.74) per share for the year, up from their previous forecast of ($1.82). HC Wainwright has a "Buy" rating and a $16.00 price objective on the stock. The consensus estimate for Astria Therapeutics' current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Astria Therapeutics' Q4 2024 earnings at ($0.50) EPS, FY2025 earnings at ($1.75) EPS, FY2026 earnings at ($1.88) EPS, FY2027 earnings at ($1.93) EPS and FY2028 earnings at ($1.62) EPS.
Several other research analysts have also recently issued reports on ATXS. Evercore ISI upgraded shares of Astria Therapeutics to a "strong-buy" rating in a report on Wednesday, August 14th. Oppenheimer increased their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a research note on Thursday. Wedbush restated an "outperform" rating and set a $22.00 price target on shares of Astria Therapeutics in a report on Tuesday, August 13th. Finally, TD Cowen initiated coverage on Astria Therapeutics in a research report on Monday, July 29th. They issued a "buy" rating and a $35.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Astria Therapeutics currently has a consensus rating of "Buy" and an average price target of $25.60.
Get Our Latest Analysis on ATXS
Astria Therapeutics Stock Down 2.2 %
Shares of Astria Therapeutics stock traded down $0.21 during trading on Monday, reaching $9.16. The company's stock had a trading volume of 354,982 shares, compared to its average volume of 612,815. The firm's 50-day moving average is $11.36 and its two-hundred day moving average is $10.62. Astria Therapeutics has a 52-week low of $4.41 and a 52-week high of $16.90. The company has a market cap of $516.94 million, a price-to-earnings ratio of -4.38 and a beta of 0.71.
Institutional Investors Weigh In On Astria Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Astria Therapeutics by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company's stock worth $35,693,000 after buying an additional 480,184 shares during the period. Tidal Investments LLC bought a new stake in shares of Astria Therapeutics in the first quarter worth about $1,664,000. Sofinnova Investments Inc. purchased a new stake in shares of Astria Therapeutics during the 2nd quarter worth approximately $552,000. ClariVest Asset Management LLC purchased a new position in shares of Astria Therapeutics in the 2nd quarter worth $731,000. Finally, Ameritas Investment Partners Inc. raised its position in shares of Astria Therapeutics by 135.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company's stock valued at $70,000 after buying an additional 2,861 shares in the last quarter. 98.98% of the stock is owned by hedge funds and other institutional investors.
Astria Therapeutics Company Profile
(
Get Free Report)
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
See Also
Before you consider Astria Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astria Therapeutics wasn't on the list.
While Astria Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.